Beyond Air (NASDAQ:XAIR) Issues Earnings Results

Posted by Brian Himes on Aug 13th, 2026

Beyond Air (NASDAQ:XAIR – Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($11.00) earnings per share for the quarter, missing analysts’ consensus estimates of ($10.80) by ($0.20), Zacks reports. Beyond Air had a negative return on equity of 350.00% and a negative net margin of 432.99%.

Here are the key takeaways from Beyond Air’s conference call:

Second-quarter revenue was $1.8 million, essentially flat year over year and sequentially. Gross margin improved to 13%, marking the third consecutive quarter of positive gross profit, although the company still reported a $7.9 million net loss.
Beyond Air raised $10 million upfront through financing with potential for up to an additional $20 million from warrant exercises, strengthening its ability to fund Gen 2 LungFit PH production, commercial preparations, and international expansion.
The company said its Gen 2 LungFit PH submission remains on track for potential FDA approval in the second half of 2026, with audits and pilot builds underway. Management described FDA communication as strong but cautioned that timing remains subject to the agency’s review.
Commercial momentum is building, including a new national group purchasing agreement that gives Beyond Air access to a substantial portion of U.S. hospitals, a pipeline that management says has doubled over the past five to six months, and distribution partnerships spanning more than 40 countries.
Management reaffirmed 2026 revenue guidance of $8 million and 2027 guidance of $16 million to $18 million; the 2027 outlook includes potential Gen 2 LungFit PH revenue, while the 2026 forecast excludes any contribution from the new system.

Beyond Air Price Performance

Beyond Air stock traded up $0.35 during midday trading on Thursday, reaching $6.41. The company had a trading volume of 30,201 shares, compared to its average volume of 163,520. The company has a debt-to-equity ratio of 3.48, a current ratio of 3.80 and a quick ratio of 3.59. Beyond Air has a 12-month low of $5.02 and a 12-month high of $95.60. The company has a market capitalization of $4.61 million, a P/E ratio of -0.07 and a beta of 0.23. The firm’s fifty day simple moving average is $7.19 and its 200-day simple moving average is $12.44.

Insider Buying and Selling

In other news, CEO Robert Scott Goodman bought 34,722 shares of Beyond Air stock in a transaction on Wednesday, July 29th. The stock was acquired at an average price of $5.76 per share, with a total value of $199,998.72. Following the completion of the acquisition, the chief executive officer directly owned 34,822 shares of the company’s stock, valued at $200,574.72. The trade was a 34,722.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 9.99% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its holdings in shares of Beyond Air by 57.5% during the fourth quarter. Geode Capital Management LLC now owns 67,678 shares of the company’s stock worth $49,000 after buying an additional 24,695 shares in the last quarter. Alyeska Investment Group L.P. acquired a new position in Beyond Air during the third quarter worth about $1,753,000. Virtu Financial LLC purchased a new stake in Beyond Air during the 3rd quarter valued at about $48,000. Finally, Osaic Holdings Inc. raised its holdings in Beyond Air by 26.4% in the 2nd quarter. Osaic Holdings Inc. now owns 162,560 shares of the company’s stock valued at $29,000 after acquiring an additional 34,000 shares during the last quarter. 31.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Beyond Air in a report on Tuesday, July 21st. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $200.00.

Read Our Latest Report on XAIR

Beyond Air Company Profile

(Get Free Report)

Beyond Air, Inc is a clinical-stage medical technology company focused on the development and commercialization of inhaled nitric oxide (NO) therapy for pulmonary and respiratory diseases. The company’s proprietary LungFit® platform delivers pulsed, low-dose nitric oxide gas through compact, portable devices designed to support treatments in both inpatient and outpatient settings. Beyond Air’s approach leverages NO’s antimicrobial, vasodilatory and anti-inflammatory properties to address a range of unmet needs in respiratory medicine.

The company’s lead candidate, LungFit® PH, is under investigation for the treatment of pulmonary hypertension, with ongoing clinical studies assessing its impact on pulmonary arterial pressure and exercise capacity.